Comparison of guidances from FDA, EMA and CFDA on the bioequivalence studies of highly variable drugs
LI Zi-qiang
HUANG Yu-hong
WANG Bao-he
LIU Chang-xiao
Keywords：highly variable drugsreference-scaled average bioequivalencepopulation bioequivalenceindividual bioequivalencereplicated crossover design
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)